Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung CancerHeather A. Wakelee, Jonathan Spicer, Moïshe Liberman et al.|New England Journal of Medicine|2023Cited by 1k
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLCShugeng Gao, Jie He, Ning Li et al.|Journal of Thoracic Oncology|2020Cited by 415
Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non–Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional RegistryWenhua Liang, Jianxing He, Jiaxi He et al.|Journal of Clinical Oncology|2017Cited by 358
METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF bindingWei Wang, Zhimin Lu, Fei Shao et al.|Nature Communications|2021Cited by 193
Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non‐small cell lung cancer patients with neoadjuvant immunotherapyQilin Huai, Shugeng Gao, Chenyu Luo et al.|Cancer Science|2023Cited by 90